Lerodalcibep for Hypercholesterolaemia

As of August 2026, MARA’s assessment finds Lerodalcibep’s reimbursement risk concentrated in comparator selection, with care pathway integration a strength; the current MARA Rating and full rationale are available in the report.

The assessment also weighs resource use and cost implications: what the drug adds to, or removes from, the wider bill beyond its own price — administration, monitoring, hospital time. The strength recorded in care pathway integration carries weight because that domain asks how the drug fits into the way care is organised today; a treatment that demands new infrastructure or displaces an established pathway faces extra scrutiny.

Cardiology

This rating sits within MARA’s Cardiology coverage, alongside 24 other independently assessed treatments in the same area.

What payers will ask

Is the clinical benefit the kind payers reward? — Clinical effectiveness

Lerodalcibep demonstrated significant LDL-C reductions (~50-60%) in Phase 3 trials, comparable to PCSK9 inhibitors. However, the absence of head-to-head trials and reliance on surrogate endpoints limit the evidence to moderate benefit.

Does the economic case hold at the expected price? — Cost effectiveness

No formal ICER or cost-utility model is available for lerodalcibep, and no economic analysis was presented.

Is there quality-of-life evidence payers weigh? — Quality of life

No HRQoL data or utility values were reported in the trials, making this domain not assessable.

Does the safety profile hold up for payers? — Safety and Adverse Effects

Lerodalcibep’s safety profile is consistent with PCSK9 inhibitors, with mild injection-site reactions and no major systemic toxicity reported. Confidence in short-term safety is high.

Was the drug compared against what payers expect? — Comparator Selection

The trials used placebo as a comparator, which is standard but limits direct comparison with active treatments like other PCSK9 inhibitors.

Is the population defined the way payers need it? — Patient Population and Subgroups

The trial population is representative of the target indications, but there are gaps in subgroup analyses and underrepresentation of certain demographics.

Does the drug fit how care is delivered and paid for? — Care Pathway Integration

Lerodalcibep integrates seamlessly into existing care pathways as an add-on therapy, with minimal training and infrastructure requirements.

Are the wider system costs understood? — Resource Use and Cost Implications

While the list price is lower than older PCSK9 agents, the lack of formal budget impact studies and outcomes data limits confidence in resource implications.

Would the evidence survive payer scrutiny? — Evidence Quality and Robustness

The evidence base consists of high-quality Phase 3 RCTs with consistent results, but lacks real-world effectiveness and long-term outcomes data.

How exposed is the case to uncertainty? — Uncertainty, Sensitivity, and Broader Impacts

High uncertainty exists due to the lack of clinical outcomes and reliance on assumptions for LDL-C lowering translating to event reduction.

This rating replaces the earlier February 2026 rating of the same drug and indication — still on the record here.

Request the current rating

Be alerted when this rating changes:

Related Reimbursement Risk Assessments

Full Legal Disclaimer and Usage Terms

The MARA Rating® is an independent opinion of a drug’s market access pharma risk profile and is provided for informational purposes only—not as investment, medical, legal or any other type of advice. See our full disclaimer here.